logo
I Wore the $599 TheraFace Mask for 3 Months, but It Didn't Change My Life

I Wore the $599 TheraFace Mask for 3 Months, but It Didn't Change My Life

WIRED01-05-2025

Every night for three months, I strapped a futuristic-looking device onto my face—something like a Stormtrooper mask designed by a spa technician from the year 3000. Depending on my mood, I toggled through the vibration therapy settings. Some nights I meditated; most nights I just lay there, scrolling through TikTok while my face bathed in red light.
This was the TheraFace Mask: an FDA-cleared LED therapy device from Therabody, the wellness brand best known for its percussive massage guns. Now, it's coming for our faces. Of course it is. LED masks are the new face of Silicon Valley's obsession with biohacking; once a splurge at the dermatologist or med spa, now gamified for skin-care girlies and longevity bros alike. You don't even need to leave your couch. Just plug in, strap up, and level up your epidermis.
The TheraFace Mask promises to smooth fine lines, brighten skin dullness, and reduce the appearance of acne with a preprogrammed nine-minute daily treatment. So I tested it: 9 minutes, five days a week, for three months straight. It didn't transform my skin, but it did feel oddly soothing in a way my usual self-care didn't. Strap In
Photograph: Dermstore
First: It's comfortable enough. The TheraFace Mask is cordless and rechargeable, with adjustable straps and removable eye shields. It's marketed as 'one size fits most,' but if you have a large head, it may feel snug. Inside the mask's hard, white shell are 648 medical-grade LEDs, triple what Therabody says you'll find in the leading competitor.
It's powered by internal lithium-ion batteries and charged via USB-C or USB-A. It holds enough power for eight to 10 full sessions, but you'll have to guess when it's low, because there's no battery indicator, for reasons I cannot comprehend at this price. Therabody also built in 17 micro QX-Motors that vibrate against pressure points on your face and scalp during treatments to up the wellness factor. The vibrations aren't strong enough to qualify as a massage—it's more of a gentle buzzing, slightly noisy but oddly soothing when you're lying down.
There's also no app. Therabody usually loves Bluetooth pairing, but in this case, you control everything with two buttons on either side of the mask, toggling through light settings and three vibration modes: Continuous, Breathing, and Wave. Thanks to the auto-cycle that runs through red, near-infrared, and blue light without needing to touch a button, the TheraFace Mask makes it easy to stick with the habit.
LED light therapy is backed by science, but with a couple of asterisks. Red light has been shown to stimulate collagen production and improve elasticity over time. Blue light is effective against acne-causing bacteria. Near-infrared light penetrates deeper, targeting inflammation and pigmentation. These results are cumulative, subtle, and definitely not instant. The Long Game
Therabody conducted a 12-week clinical study with 31 participants aged 39 to 64 with a variety of skin tones. After following a regimen similar to mine, 93 percent reported fewer fine lines, 86 percent noted better tone, and 77 percent saw improvement in age spots. That's promising but not definitive. Thirty-one people is a small sample size, and the study doesn't break down how different skin tones or ages responded.
Still, the TheraFace mask is powerful. It boasts some of the highest irradiance levels (fancy words for how much light your skin absorbs) we've tested in consumer devices. Three minutes of red light treatment with the TheraFace matches the output of other popular devices' longer sessions. The light also spills onto the neck; it's nowhere near as effective as a décolletage mask but still a nice bonus.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold
SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold

Yahoo

time41 minutes ago

  • Yahoo

SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold

SCYNEXIS, Inc. (NASDAQ:SCYX) has officially restarted patient dosing in its Phase III MARIO trial for Brexafemme (ibrexafungerp) after the FDA lifted a nearly two-year clinical hold. The hold, initiated over concerns of beta-lactam contamination at the original manufacturing facility, was removed once new drug batches were produced at a separate location. With trial sites now reactivated, patient enrollment has resumed, reaching about 25% of its 220-participant goal. A pharmacist technician sorting pills in a drug pharmacy. The MARIO trial explores Brexafemme's use as an oral follow-up treatment to IV echinocandins for invasive candidiasis, a life-threatening fungal infection. SCYNEXIS, Inc. (NASDAQ:SCYX) received a $10 million milestone payment from GSK after the first new patient was dosed, though disagreements over further payments and trial duties have sparked tension between the two partners. Previously recalled in 2023 due to contamination risks, Brexafemme had FDA approval for treating VVC. While its commercial progress has faced setbacks, projected global revenue could reach $139 million by 2031 if development succeeds. While we acknowledge the potential of SCYX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SCYX and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data
Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data

Yahoo

timean hour ago

  • Yahoo

Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi SA (NASDAQ:SNY) on Friday announced results from two Phase 3 trials of itepekimab in chronic obstructive pulmonary disease (COPD) patients. Phase 3 AERIFY-1 trial evaluating itepekimab in adults who were former smokers with inadequately controlled COPD met the primary endpoint of significantly reducing moderate or severe acute exacerbations by 27% compared to placebo at week 52, a clinically meaningful benefit. A second Phase 3 trial, AERIFY-2, did not meet the same primary endpoint. Despite showing some benefit earlier in the trial (at week 24), itepekimab did not achieve a statistically significant reduction in moderate or severe exacerbations at week 52 in the second the trials, patients were randomized to receive itepekimab every two weeks (AERIFY-1: n=375; AERIFY-2: n=326), every four weeks (AERIFY-1: n=377; AERIFY-2: n=303), or placebo (AERIFY-1: n=375; AERIFY-2: n=324), which was added to inhaled triple or double standard-of-care therapy. The primary endpoint for AERIFY-1 and AERIFY-2 was the reduction in the annualized rate of acute moderate or severe COPD exacerbations with itepekimab treatment. The total number of exacerbations was lower than prospectively anticipated, decreasing the power of both trials. Enrollment largely occurred during the global COVID-19 pandemic, which could have contributed to the lower overall exacerbation rates. The safety profile of itepekimab was consistent across dosing regimens, and adverse events (AEs) were generally comparable between treatment and placebo groups. Regeneron and Sanofi will review the data and discuss it with regulatory authorities to evaluate the next steps. Itepekimab is also being evaluated in other respiratory conditions, including chronic rhinosinusitis without nasal polyps, chronic rhinosinusitis with nasal polyps, and non-cystic fibrosis bronchiectasis. In November 2024, Regeneron and Sanofi's Dupixent gained FDA approval for COPD, marking its sixth U.S. indication since its first use for atopic dermatitis seven years ago. This expansion positions Dupixent as the first targeted therapy for COPD, a significant leap in treating this progressive lung condition that impedes breathing due to obstructed airflow. Last Thursday, the U.S. Food and Drug Administration (FDA) approved GSK Plc's (NYSE:GSK) Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled COPD and an eosinophilic phenotype. Last June, the FDA approved Verona Pharma plc's (NASDAQ:VRNA) Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. Ohtuvayre is the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years. In May, Sanofi announced it will invest at least $20 billion in the U.S. through 2030. Research and development, plus U.S. manufacturing, will receive the bulk of the spending. The company also expects higher job creation within the communities where Sanofi and its partners are located, which will help enhance the U.S. supply chain. Earlier in May, Regeneron secured the winning bid in the bankruptcy auction for key assets of 23andMe Holding Co. in a $256 million deal to boost its genetics-based drug discovery efforts. Price Action: REGN stock is down 9.98% at $545, and SNY stock is down 4.57% at $49.96 during the premarket session at last check Friday. Read Next:Photo by Marianne Campolongo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? REGENERON PHARMACEUTICALS (REGN): Free Stock Analysis Report SANOFI (SNY): Free Stock Analysis Report This article Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio

Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2025 MedTech Innovation Spotlight
Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2025 MedTech Innovation Spotlight

Yahoo

timean hour ago

  • Yahoo

Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2025 MedTech Innovation Spotlight

MINNEAPOLIS, May 30, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will participate in the Wells Fargo 2025 MedTech Innovation Spotlight on Friday, June 13, 2025. Inspire is scheduled to present at 12:00 p.m. Eastern Time. The presentation will be accessible via a live webcast here. A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire's Investor website at About Inspire Medical SystemsInspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire's proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire, please visit Investor and Media ContactEzgi YagciVice President, Investor Relationsezgiyagci@ in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store